Horizon Therapeutics Plc Announces New Analysis Highlights Importance Of Adhering To Uninterrupted Full Course Of Treatment With TEPEZZA To Support Thyroid Eye Disease Patient Outcomes
Portfolio Pulse from Benzinga Newsdesk
Horizon Therapeutics (NASDAQ:HZNP) has announced new data showing that disrupting the recommended TEPEZZA treatment regimen for Thyroid Eye Disease (TED) can increase the need for a second course of treatment. The majority of treatment disruptions were related to the short-term TEPEZZA supply disruption that occurred in late 2020 due to government-mandated COVID-19 vaccine production orders. The company also presented further results from the TEPEZZA Phase 4 clinical trial and research on the impact of TED on patients' quality of life.
September 29, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Horizon Therapeutics' new data emphasizes the importance of uninterrupted TEPEZZA treatment for Thyroid Eye Disease. Disruptions in treatment, largely due to COVID-19 vaccine production orders, can necessitate a second course of treatment.
The new data from Horizon Therapeutics emphasizes the importance of uninterrupted treatment with TEPEZZA for Thyroid Eye Disease. This could potentially impact the company's reputation and sales if patients or healthcare providers perceive the treatment as unreliable due to the potential need for a second course of treatment. However, the impact on the stock price is uncertain as the disruption was largely due to external factors (COVID-19 vaccine production orders) and the company has presented further positive results from the TEPEZZA Phase 4 clinical trial.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100